Virtu Financial’s Cardiol Therapeutics CRDL Stock Holding History

Virtu Financial’s Portfolio CRDL Stock Details CRDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-23,917	Closed	-$32K	–	1708
2026 Q1	$32K	Buy	+23,917	New	+$24.5K	﹤0.01%	1344
2025 Q4	–	Sell	-144,062	Closed	-$154K	–	1764
2025 Q3	$154K	Buy	+144,062	New	+$175K	0.01%	964
2025 Q2	–	Sell	-16,038	Closed	-$16K	–	1559
2025 Q1	$16K	Sell	16,038 -31,993	-67%	-$39.3K	﹤0.01%	1132
2024 Q4	$61K	Buy	+48,031	New	+$81K	﹤0.01%	1123
2022 Q1	–	Sell	-14,812	Closed	-$27K	–	1581
2021 Q4	$27K	Sell	14,812 -61,007	-80%	-$168K	﹤0.01%	1471
2021 Q3	$315K	Buy	+75,819	New	+$275K	0.03%	691

Other funds holding CRDL

MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Integrity Alliance Urbandale, Iowa $3.2B AUM 23.28% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Virtu Financial's CRDL Position: Q2 2026 in Review

Virtu Financial sold out of Cardiol Therapeutics (CRDL) in Q2 2026, closing a stake of 23,917 shares — an estimated $32K sold.

Virtu Financial first reported a position in CRDL in Q3 2021 and held it in 6 quarters. The position peaked at $315K in Q3 2021. 52 funds tracked by Wall St. Rank hold CRDL as of Q2 2026.

Virtu Financial reported no remaining Cardiol Therapeutics position as of Q2 2026 after selling out during the quarter.
Virtu Financial sold 23,917 Cardiol Therapeutics shares in Q2 2026, an estimated $32K.
Virtu Financial first reported a position in Cardiol Therapeutics in Q3 2021 and held it in 6 quarters.
Virtu Financial's Cardiol Therapeutics position peaked at $315K in Q3 2021.
52 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.